Abstract
Chimeric or hybrid herpes simplex virus type 1/adeno-associated virus amplicon vectors combine the large transgene capacity of HSV-1 with the potential for site-specific genomic integration and stable transgene expression of AAV. These chimeric vectors have been demonstrated to support transgene expression for significantly longer periods than standard HSV-1 amplicons. Moreover, HSV/AAV hybrid vectors can mediate integration at the AAVS1 preintegration site on human chromosome 19 at a relatively high rate, although random integration has also been observed. One major remaining hurdle of HSV/AAV hybrid vectors is the low packaging efficiency and titers when AAV rep sequences are included in the amplicon vector. In the conditions prevalent during the replication/packaging of HSV/AAV hybrid amplicons into HSV-1 virions, in particular the presence of HSV-1 replication factors and AAV Rep protein, at least three different viral origins of DNA replication are active: the HSV-1 ori, the AAV inverted terminal repeats (ITRs), and the p5 promoter/ori driving expression of the AAV rep gene. A detailed understanding of the properties of these origins of DNA replication and the molecular mechanisms of interactions between them, may allow designing novel hybrid vectors that allow the efficient and precise integration of large transgenes in the human genome.
Keywords: HSV/AAV hybrid amplicon, site-specific integration, virus-virus interaction, replication compartment
Current Gene Therapy
Title: Chimeric Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors
Volume: 6 Issue: 3
Author(s): Daniel L. Glauser, Mathias Ackermann, Okay Saydam and Cornel Fraefel
Affiliation:
Keywords: HSV/AAV hybrid amplicon, site-specific integration, virus-virus interaction, replication compartment
Abstract: Chimeric or hybrid herpes simplex virus type 1/adeno-associated virus amplicon vectors combine the large transgene capacity of HSV-1 with the potential for site-specific genomic integration and stable transgene expression of AAV. These chimeric vectors have been demonstrated to support transgene expression for significantly longer periods than standard HSV-1 amplicons. Moreover, HSV/AAV hybrid vectors can mediate integration at the AAVS1 preintegration site on human chromosome 19 at a relatively high rate, although random integration has also been observed. One major remaining hurdle of HSV/AAV hybrid vectors is the low packaging efficiency and titers when AAV rep sequences are included in the amplicon vector. In the conditions prevalent during the replication/packaging of HSV/AAV hybrid amplicons into HSV-1 virions, in particular the presence of HSV-1 replication factors and AAV Rep protein, at least three different viral origins of DNA replication are active: the HSV-1 ori, the AAV inverted terminal repeats (ITRs), and the p5 promoter/ori driving expression of the AAV rep gene. A detailed understanding of the properties of these origins of DNA replication and the molecular mechanisms of interactions between them, may allow designing novel hybrid vectors that allow the efficient and precise integration of large transgenes in the human genome.
Export Options
About this article
Cite this article as:
Glauser L. Daniel, Ackermann Mathias, Saydam Okay and Fraefel Cornel, Chimeric Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors, Current Gene Therapy 2006; 6 (3) . https://dx.doi.org/10.2174/156652306777592090
DOI https://dx.doi.org/10.2174/156652306777592090 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Current Radiopharmaceuticals The Cytoprotective and Anti-cancer Potential of Bisbenzylisoquinoline Alkaloids from <I>Nelumbo nucifera</I>
Current Topics in Medicinal Chemistry Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer’s Disease
Current Topics in Medicinal Chemistry Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Recent Advances in the Development of Thioredoxin Reductase Inhibitors as Anticancer Agents
Current Drug Targets The Heterogeneity of Glioma Stem Cells
Current Signal Transduction Therapy The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry
Current Medicinal Chemistry An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
Current Genomics The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism The Coronin Family and Human Disease
Current Protein & Peptide Science